ABCAM PLC/ADR (OTCMKTS:ABCZY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Separately, ValuEngine cut shares of ABCAM PLC/ADR from a “buy” rating to a “hold” rating in a report on Friday, December 21st.
Shares of OTCMKTS ABCZY opened at $16.28 on Thursday. ABCAM PLC/ADR has a 1 year low of $12.52 and a 1 year high of $20.29.
About ABCAM PLC/ADR
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Recommended Story: Cost of Equity For A Business, Investors
Get a free copy of the Zacks research report on ABCAM PLC/ADR (ABCZY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABCAM PLC/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABCAM PLC/ADR and related companies with MarketBeat.com's FREE daily email newsletter.